Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Ascending Dose Trial of Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered to Subjects at the Time of Resection for Recurrent High Grade Glioma & Followed by Treatment With Toca FC, Extended-Release 5-FC

NCT01470794 is registered in ClinicalTrials.gov with Tocagen Inc. as lead sponsor.

NCT NCT01470794
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01470794 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Ascending Dose Trial of Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered to Subjects at the Time of Resection for Recurrent High Grade Glioma & Followed by Treatment With Toca FC, Extended-Release 5-FC
Lead sponsor
Tocagen Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 29, 2012
Completion date
April 12, 2016
Enrollment
58 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, glioblastoma multiforme